eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank
1/2021
vol. 25
 
Share:
Share:
more
 
 
abstract:
Review paper

Immunotherapy in patients with non-small cell lung cancer with ECOG PS 2

Damian Mojsak
1
,
Beata Kuklińska
1
,
Michał Dębczyński
1
,
Robert Marek Mróz 
1

1.
Second Department of Lung Diseases and Tuberculosis, Medical University of Białystok, Białystok, Poland
Contemp Oncol (Pozn) 2021; 25 (1): 53-56
Online publish date: 2021/04/06
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Immunotherapy is a new and very pro­mising method of anti-cancer treat­ment. Unfortunately, not every patient can benefit from this treatment. The Polish drug program determines the selection of patients based on PD-L1 expression and the performance status assessed with the use of Eastern Cooperative Oncology Group Perfor­mance Status (ECOG PS) score. Patients with ECOG PS 2 represent a sig­nificant proportion of the cancer population, one which is overlooked in most clinical trials of immunotherapy. Often, a reduced performance status is the only factor that excludes the patient from treatment with immunotherapy. Choosing the optimal method of treatment in patients with a worse general condition and with multiple diseases may be a significant problem for the doctor. Assessment of performance status may be a particular problem because not every patient has a worse PS score for the same reasons. In this study, we analyse the results of treatment of patients with a poorer performance status to date, and we present tools that improve the precise assessment of the degree of the performance status, which may enable more patients to access novel lung cancer treatments.
keywords:

non-small cell lung cancer, immunotherapy, performance status

Quick links
© 2021 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe